Galectin Therapeutics (GALT) Notes Payables (2024 - 2026)
Galectin Therapeutics (GALT) posted quarterly Notes Payables of $3.7 million for Q3 2025, up 942.34% year-over-year from $359000.0 in Q3 2024, and up 1126.89% quarter-over-quarter from $305000.0 in Q1 2025.
Powered by 
Analysis
Galectin Therapeutics (GALT) Notes Payables (2024 - 2026) Analysis & Trends
Galectin Therapeutics' Notes Payables history runs 2 years deep, the most recent figure standing at $3.7 million for Q3 2025.
- In Q3 2025, Notes Payables rose 942.34% year-over-year to $3.7 million; the TTM figure through Sep 2025 stood at $3.7 million (up 942.34% YoY), while the FY2024 annual figure was $369000.0, changed N/A from the prior year.
- Notes Payables for Q3 2025 stood at $3.7 million, up from $305000.0 in the prior quarter.
- The five-year high for Notes Payables was $3.7 million in Q3 2025, with the low at $305000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Galectin Therapeutics | 304.34 Mn | 304.34 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 33.04 Mn |
| Sep 30, 2025 | 32.52 Mn |
| Mar 31, 2025 | 21.28 Mn |
| Dec 31, 2024 | 21.12 Mn |
| Sep 30, 2024 | 10.52 Mn |